DexCom’s (DXCM) “Hold” Rating Reaffirmed at BTIG Research

BTIG Research reiterated their hold rating on shares of DexCom (NASDAQ:DXCM) in a research note issued to investors on Thursday, AnalystRatings.com reports.

A number of other research analysts also recently commented on the company. ValuEngine raised DexCom from a buy rating to a strong-buy rating in a research note on Friday, June 21st. Zacks Investment Research raised DexCom from a hold rating to a buy rating and set a $138.00 price target for the company in a research note on Monday, May 6th. Piper Jaffray Companies boosted their price target on DexCom from $173.00 to $182.00 and gave the company a positive rating in a research note on Wednesday. BidaskClub raised DexCom from a hold rating to a buy rating in a research note on Tuesday, July 23rd. Finally, BMO Capital Markets boosted their price target on DexCom from $167.00 to $172.00 and gave the company an outperform rating in a research note on Thursday, May 2nd. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $163.71.

Shares of DexCom stock traded down $4.11 during trading on Thursday, reaching $144.21. The company’s stock had a trading volume of 1,203,317 shares, compared to its average volume of 1,244,951. The firm has a market capitalization of $14.24 billion, a price-to-earnings ratio of 480.70 and a beta of 0.82. The firm’s 50-day moving average price is $149.93. DexCom has a 52 week low of $105.05 and a 52 week high of $161.30. The company has a debt-to-equity ratio of 1.57, a quick ratio of 6.75 and a current ratio of 7.18.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, July 31st. The medical device company reported $0.08 EPS for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.07. The business had revenue of $336.40 million during the quarter, compared to the consensus estimate of $304.40 million. DexCom had a positive return on equity of 8.45% and a negative net margin of 11.51%. DexCom’s revenue for the quarter was up 38.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.10) earnings per share. On average, equities analysts forecast that DexCom will post 0.81 EPS for the current year.

In other DexCom news, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $115.73, for a total transaction of $694,380.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Steven Robert Pacelli sold 3,597 shares of the business’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $116.71, for a total value of $419,805.87. Following the transaction, the executive vice president now directly owns 72,570 shares of the company’s stock, valued at approximately $8,469,644.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 63,065 shares of company stock valued at $8,207,313. Insiders own 1.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Gradient Investments LLC bought a new stake in shares of DexCom during the second quarter worth about $25,000. Steward Partners Investment Advisory LLC bought a new stake in shares of DexCom during the second quarter worth about $31,000. Private Ocean LLC bought a new stake in shares of DexCom during the first quarter worth about $36,000. Wealthcare Advisory Partners LLC bought a new stake in shares of DexCom during the second quarter worth about $37,000. Finally, Canton Hathaway LLC bought a new stake in shares of DexCom during the first quarter worth about $41,000. 96.27% of the stock is owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: Why are gap-down stocks important?

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.